Fetuin-A gene polymorphism and its serum level association with atherosclerotic vascular disease in type 2 diabetes patients with early diabetic kidney disease

Eman Y. Morsy¹, Neveen L. Saad², Hesham A. Elghoneimy¹, Abd Alhalim G. Smeida³, Azza A. Ismail¹,∗

ABSTRACT

Background: The incidence of type 2 diabetes mellitus (T2DM) is increasing over the past years. Early identification and management of its complications, especially diabetic kidney disease (DKD), is of great importance. Multiple factors play a role in the pathogenesis of T2DM and DKD. We aimed to study Fetuin-A gene polymorphisms and Fetuin-A serum levels in T2DM patients with early DKD.

Methods: The present work was conducted on 120 patients with T2DM (60 patients with microalbuminuria and 60 without albuminuria), and 30 healthy subjects (as a control group). Serum Fetuin-A levels were measured with ELISA. Fetuin-A, Thr256Ser and Thr248Met polymorphisms were determined by PCR-RFLP.

Results: Patients with T2DM had a significantly higher mean serum Fetuin-A compared to controls (p < 0.001), while no difference was observed when comparing mean serum Fetuin-A in patients with microalbuminuria and patients without albuminuria (p = 0.916). Multivariate regression analysis demonstrated that carotid intima-media thickness (CIMT) and insulin resistance had positive correlations with serum Fetuin-A (p < 0.001 and p < 0.001, respectively). Ankle-brachial pressure index (ABPI) had a negative correlation with serum Fetuin-A (p = 0.046), while Fetuin-A levels neither affected eGFR nor albuminuria. The distribution of the alleles of both polymorphisms showed increased frequency of TT (rs248) and GG (rs256) in patients with microalbuminuria compared to patients without albuminuria. Conclusion: increased serum Fetuin-A is associated with insulin resistance and increased risk of atherosclerosis in patients with T2DM, but is not associated with the development of DKD. TT (rs248) and GG (rs256) polymorphisms may be associated with lower risk of DKD.

Key words: Type 2 diabetes, Fetuin-A, Diabetic kidney disease, albuminuria

INTRODUCTION

Diabetes mellitus (DM) is one of the most frequent chronic diseases worldwide. It is an important cause of morbidity and mortality in developed countries and is becoming an epidemic in developing countries ¹. Type 2 diabetes mellitus (T2DM) is the most prevalent form of the disease, representing 90 — 95% of cases of DM ². The frequency of chronic complications due to microvascular (e.g., diabetic kidney disease, neuropathy and retinopathy) and macrovascular (e.g., stroke, coronary artery disease and peripheral artery disease) alterations, as well as the difficulties in controlling T2DM, make it a great medical challenge ³.

DM is also a strong risk factor for peripheral artery disease (PAD), including atherosclerosis in lower extremity arteries and carotid artery disease ⁴,⁵. PAD represents a significant burden to health care and is considered to be a major cause of myocardial infarction, stroke and amputation ⁶,⁷. Moreover, both DM and PVD are associated with increased long-term mortality ⁸,⁹. The cause of PAD in T2DM is multifactorial as it involves macrovascular affection, vascular inflammation, peripheral neuropathy, increased susceptibility to infections, microvascular affection, and poor wound healing ¹⁰,¹¹.

Diabetic kidney disease (DKD) is a syndrome defined as progressive increase in the urinary albumin excretion associated with glomerular lesions, leading to loss of glomerular filtration and eventually end-stage renal disease (ESRD) ¹². DKD affects about 20–40% of patients with diabetes and is a leading cause of ESRD worldwide ¹³. DKD was previously known as diabetic nephropathy but now, DKD is a broader term including not only diabetic nephropathy but also atheroembolic disease, ischemic nephropathy and interstitial fibrosis, which occur as a direct result of diabetes ¹⁴. Patients with chronic kidney disease (CKD) are more likely to develop atherosclerotic cardiovascular disease and atherosclerotic PAD than the general population with preserved kidney function ¹⁵,¹⁶. Moreover,
the presence of PAD in CKD patients markedly increases the short-term risk of ischemic cardiac events and stroke. Albuminuria develops as a renal manifestation of generalized vascular endothelial injury, making it a valuable early predictor of atherosclerosis and cardiovascular mortality. Early identification and treatment of patients at increased risk for albuminuria may be important to limit the excess renal and cardiovascular diseases associated with type 2 diabetes.

Fetuin-A is a multifunctional plasma agent with a molecular weight of approximately 60 kDa and half-life of several days. During fetal development, Fetuin-A is abundantly synthesized by multiple tissues. In adults, it is secreted predominantly by the liver. Fetuin-A is a physiological inhibitor of insulin receptor tyrosine kinase, and thus is associated with insulin resistance and an increased risk for T2DM. Moreover, Fetuin-A knockout mice demonstrated increased basal and insulin-stimulated phosphorylation of insulin receptor, increased glucose clearance, and improved insulin sensitivity. Additionally, fetuin-null mice were protected from weight gain when they were challenged with a high-fat diet.

SUBJECTS — METHODS

This cross-sectional case-control study was conducted on 150 subjects who were divided into three groups: group A (60 patients with T2DM and microalbuminuria), group B (60 patients with T2DM without albuminuria), and group C (30 healthy control subjects matched for age, sex and socioeconomic status). The criteria for patients for inclusion in the study were that patients (either male or female) had T2DM disease, with or without DKD. Exclusion criteria were as follows: patients with a history of acute coronary syndrome (e.g., unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI)), history and clinical examination suggestive of peripheral vascular disease, prior stroke or transient ischemic attack, endocrinical or metabolic diseases other than T2DM, gestational diabetes, type 1 diabetes, and/or severe renal or hepatic impairment.

All the participants included in the study were informed about the nature of the study, and their oral and written consent for voluntary participation in the study were obtained. The approval of the Ethics Committee of the Alexandria University, Faculty of Medicine was also obtained (project number: 0201034).

For all the subjects in our study, a full history was taken with special emphasis on different cardiovascular risk factors and detailed drug use. Complete physical examinations were done and anthropometric measurements were calculated; body mass index (BMI) was calculated as weight/height^2 (in meters), and waist circumference (WC) was measured at the midpoint between the highest point of the iliac crest and lowest point of the costal margin at the end of normal expiration.

Laboratory Investigations

Early morning urine sample was obtained for complete urine analysis and assessment of urinary albumin to creatinine ratio (ACR). Urinary ACR of < 30 mg/g creatinine was categorized as normoalbuminuria, while ACR in the range of 30–300 mg/g creatinine was categorized as microalbuminuria.

Blood sampling: sampling was done in the morning (8.00 - 10.00 AM) after overnight fasting of 12 hours. Venous blood samples were withdrawn from each subject and divided into appropriate vacutainers. Serum samples were divided into a sample for assessment of total serum cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDL-C), serum triglycerides, glycated hemoglobin (HbA1c), and fasting serum insulin level (by ELISA; kit obtained from Chemux Bioscience, Inc., San Francisco, CA, USA). Some of the serum samples were also aliquoted and stored at -80°C for further estimation of serum Fetuin-A level, as assessed using a commercially available ELISA kit (R&D Systems, Minneapolis, MN, USA).

Fetuin-A gene polymorphisms

Fetuin-A Thr256Ser and Thr248Met gene polymorphisms were determined by Polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) assay. DNA extraction: genomic DNA were extracted by use of Qiagen Genomic DNA Purification Kit (Qiagen, Germany).

Amplification: Fetuin-A Thr248Met and Thr256Ser polymorphisms were amplified using the primers supplied by Applied Biosystems (Thermo Fisher, CA). We received validation of the primers as part of the manufacturing process. The sequence of the primers were 5’- CCTCCCACAAGCA-GAAAC -3’ / 5’- TGATGATTCCGCATATC-3’, and 5’-TCACCCCTCCTGGTAAC-3’ / 5’-CCCAATGAGACCACA-3’, for the Thr248Met and Thr256Ser polymorphisms, respectively. The test
was done in a 50-mL reaction volume containing approximately 65 ng of genomic DNA, 25 pmol of each primer, 1.5 U of Taq DNA polymerase (Analysis) in 1X Reaction Buffer, and 0.25 mM of each deoxynucleotide triphosphate (Analysis). The PCR conditions were as follows: initial denaturation at 95°C for 5 min, 35 cycles of denaturation at 95°C for 1 min, annealing at 56°C for 1 min, and extension at 72°C for 1 min; followed by a final extension at 72°C for 7 min. The obtained fragments were run on agarose gel; the bands were 366-bp (for Thr248Met polymorphism) and 405 bp (for Fetuin-A Thr256Ser polymorphism).

Digestion: fragments for Thr248Met polymorphism were digested at 37°C with 2.5 U of NlaIII overnight and separated on a 2% agarose gel, while those for the Fetuin-A Thr256Ser polymorphism were digested at 37°C with 5 U of SacI (restriction enzyme) overnight and separated on a 1.5% agarose gel. For T256S, the c.766C allele remained undigested, whereas the c.766G allele yielded 193-bp and 212-bp fragments. For T248M, the c.742T allele yielded 165-bp and 201-bp fragments, whereas the c.742C allele remained undigested.

Calculations
Calculation of estimated GFR (eGFR) was done using the CKD-EPI equation.24 Assessment of insulin resistance was done using the Homeostasis Model Assessment 2 (HOMA2) calculator, released by the Diabetes Trials Unit, University of Oxford (HOMA Calculator).25 Ankle-brachial pressure index (ABPI) was calculated as the ratio of the systolic pressure from the posterior tibial at the ankle to the systolic pressure from the brachial artery. Peripheral arterial disease (PAD) was defined as an ABPI of < 0.9 in at least one leg. The lower ABPI between the two legs was used to define PAD.

Imaging
Ultrasound on the carotid artery was done to determine the carotid intima-media thickness (CIMT).

Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (IBM Corp, Armonk, NY, USA). The Kolmogorov-Smirnov test was used to verify the normality of distribution. Statistical significance of the obtained results was set at the 5% level. Correlations between quantitative continuous variables and parameters were evaluated by multivariate regression analysis. The population of the studied sample was assessed to determine its equilibrium with the Hardy-Weinberg equation.

RESULTS
This cross-sectional study was conducted on 120 patients with T2DM (60 patients with microalbuminuria and 60 patients without albuminuria) and 30 healthy subjects (as a control group).

General characteristics
There was no statistically significant difference between the three groups regarding gender distribution (p = 0.149) or age (p = 0.065). Patients with T2DM had higher BMI and higher waist-hip ratio compared to control group (p < 0.001 and p < 0.001, respectively). Systolic, diastolic and mean blood pressure levels were higher in patients with T2DM compared to control group (p < 0.001, p < 0.001 and p < 0.001, respectively). No significant differences regarding any of the above mentioned parameters were observed when comparing patients with T2DM and microalbuminuria to those with T2DM without albuminuria (p = 0.754, p = 0.073, p = 0.145, p = 0.258 and p = 0.157, respectively), as shown in Table 1.

Laboratory and radiological parameters
There was no significant difference regarding mean total cholesterol and mean HDL-C between the three groups (p = 0.572 and p = 0.095, respectively). However, serum triglyceride levels were significantly different between the groups; group C showed significantly lower mean serum triglyceride compared to group B and group A (p = 0.041 and p < 0.001, respectively). There was no difference between groups A and B regarding mean HbA1c percentage and mean HOMA2 (p = 0.692 and p = 0.085, respectively). Group A showed significantly lower mean eGFR compared to group B (p < 0.001). Also, group A showed higher mean albumin/creatinine ratio and higher mean fasting insulin compared to group B (p < 0.001 and p < 0.001, respectively). Regarding mean CIMT, both groups A and B showed significantly higher mean CIMT compared to control group (p < 0.001 and p = 0.007, respectively) and group A showed significantly higher mean CIMT compared to group B (p < 0.001). Regarding mean ABPI, group C showed a significant higher mean ABPI compared to both groups A and B (p = 0.006 and p = 0.045, respectively), while no statistically significant difference regarding mean ABPI was observed between groups A and B (p = 0.671). Laboratory and radiological parameters are shown in Table 2.
Table 1: Basic clinical characteristics of studied groups

|                                | Cases with T2DM | Control Group | p1 | p2 | p3 |
|--------------------------------|-----------------|---------------|----|----|----|
|                                | With microalbuminuria | Without albuminuria |    |    |    |
| BMI (kg/m^2)                   | Mean ± SD       | Mean ± SD     |    |    |    |
|                                | 35.47 ± 5.18    | 36.18 ± 6.68  | 23.84 ± 1.84 | 0.754 | <0.001 | <0.001 |
| Waist hip ratio                | Mean ± SD       | Mean ± SD     |    |    |    |
|                                | 1.02 ± 0.08     | 0.99 ± 0.09   | 0.87 ± 0.05  | 0.073 | <0.001 | <0.001 |
| Systolic blood pressure (mm Hg)| Mean ± SD       | Mean ± SD     |    |    |    |
|                                | 127.2 ± 10.55   | 123.8 ± 9.71  | 115.0 ± 7.31 | 0.145 | <0.001 | <0.001 |
| Diastolic blood pressure (mm Hg)| Mean ± SD       | Mean ± SD     |    |    |    |
|                                | 81.50 ± 8.04    | 79.33 ± 7.33  | 73.33 ± 6.74 | 0.258 | <0.001 | <0.001 |
| Mean arterial blood pressure (mm Hg)| Mean ± SD   | Mean ± SD     |    |    |    |
|                                | 96.45 ± 8.14    | 93.90 ± 7.42  | 86.80 ± 6.56 | 0.157 | <0.001 | <0.001 |

p1: p value for comparing between diabetic patients with microalbuminuria and diabetic patients without albuminuria; p2: p value for comparing between diabetic patients with microalbuminuria and control group; p3: p value for comparing between diabetic patients without albuminuria and control group. Statistically significant at p ≤ 0.05

Serum Fetuin-A levels
Mean serum Fetuin-A was 528.7 ± 99.35 μg/mL for group A, 514.2 ± 80.64 μg/mL for group B, and 369.0 ± 79.01 μg/mL for group C. Groups A and B showed a significant higher mean serum Fetuin-A than group C (p < 0.001 and p < 0.001, respectively), while there was no statistically significant difference between groups A and B (p = 0.916), indicating that increased serum Fetuin was present in T2DM but not related to DKD.

Correlation between serum Fetuin-A and different parameters
Regarding age, there was no significant correlation between age and serum Fetuin-A for all groups, while Fetuin-A levels seemed to be higher in females (p = 0.003). There was a statistically significant positive correlation between BMI, waist circumference, waist hip ratio, and serum Fetuin-A. Also, there were statistically significant positive correlations between HOMA2, albumin/creatinine ratio, and serum Fetuin-A. There was a statistically significant positive correlation between CIMT and serum Fetuin-A, while there was a statistically significant negative correlation between ABPI and serum Fetuin-A. There was no significant correlation of serum Fetuin-A with mean arterial blood pressure, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-C, serum triglycerides, ALT, fasting insulin, or eGFR.

A multivariate regression analysis was done, which took into consideration all the parameters affecting serum Fetuin-A levels. The significant factors positively affecting serum Fetuin-A were found to be the following: BMI, waist circumference, waist hip ratio, HOMA2 and CIMT (p = 0.013, p = 0.011, p = 0.006, p < 0.001 and p < 0.001, respectively), while ABPI was negatively correlated with Fetuin-A levels (p = 0.046).

Fetuin gene polymorphisms frequencies in the three groups
The distribution of the studied polymorphisms was consistent with the Hardy Weinberg distribution. The distribution of the different alleles in the three groups is shown in Figure 2 and Figure 3. Regarding rs248, the frequency of the CC allele was 76.7 % for group A, 73.3 % for group B, and 90.0 % for group C, with no significant difference in distribution between the groups. The frequency of the CT allele was 23.3 % for group A, 6.7 % for group B, and 10.0 % for group C. The frequency of the TT allele was 0.0 % for group A, 20.0 % for group B, and 0.0 % for group C. Regarding rs256, the frequency of the CC allele was 73.3 % for group A, 76.7% for group B, and 80.0 % for group C. Moreover, the frequency of the CG allele was 26.7 % for group A, 6.7 % for group B, and
**Table 2: Laboratory and radiological investigations of studied groups**

|                         | Cases with T2DM                  | Control Group | \( p_1 \)   | \( p_2 \)   | \( p_3 \)   |
|-------------------------|----------------------------------|---------------|-------------|-------------|-------------|
|                         | With microalbuminuria | Without albuminuria |             |             |             |
| **Triglycerides (mg/dl)** | 208.5 ± 65.19      | 179.1 ± 97.89  | 136.6 ± 19.02 | < 0.001     | < 0.001     | 0.041       |
| **HbA1C (%)**            | 8.77 ± 1.83         | 8.53 ± 1.70    | 5.25 ± 0.15  | 0.692       | < 0.001     | < 0.001     |
| **Fasting insulin (mI/UL)** | 84.60 ± 67.46     | 40.51 ± 35.62  | 13.56 ± 5.46 | < 0.001     | < 0.001     | < 0.001     |
| **HOMA2**                | 10.0 ± 4.25         | 7.93 ± 3.79    | 1.20 ± 0.24  | 0.085       | < 0.001     | < 0.001     |
| **GFR (mL/min - 1.73 m²)** | 73.90 ± 13.39      | 86.97 ± 17.82  | 99.39 ± 6.33 | < 0.001     | < 0.001     | < 0.001     |
| **Albumin/Creatinine ratio (mg/g)** | 198.3 ± 56.63 | 20.92 ± 5.89   | 11.30 ± 6.97 | < 0.001     | < 0.001     | < 0.001     |
| **CIMT (mm)**            | 0.99 ± 0.19         | 0.83 ± 0.16    | 0.71 ± 0.15  | < 0.001     | < 0.001     | 0.007       |
| **ABI**                  | 0.89 ± 0.16         | 0.92 ± 0.16    | 1.0 ± 0.13   | 0.671       | 0.006       | 0.045       |

ALT: Alanine aminotransferase; eGFR: estimated glomerular filtration rate; HOMA2: Homeostasis Model Assessment 2; CIMT: carotid intima-media thickness; ABI: Ankle Brachial Index; \( p_1 \): \( p \) value for comparing between diabetic patients with microalbuminuria and diabetic patients without albuminuria; \( p_2 \): \( p \) value for comparing between diabetic patients with microalbuminuria and control group; \( p_3 \): \( p \) value for comparing between diabetic patients without albuminuria and control group. Statistically significant at \( p \leq 0.05 \)

20.0 % for group C; the frequency of the GG allele was 0.0 % for group A, 16.7 % for group B, and 0.0 % for group C. Upon comparing the distribution of alleles, there was a significant difference in the distribution of the alleles of both polymorphisms between groups A and B, with an increased frequency of TT in rs248 and increased frequency of GG in rs256 in group B, compared to group A. T allele (rs248) was more dominant in patients with T2DM and without proteinuria (OD of 2.304 at CI of 95%). Regarding rs256, the GG polymorphism was more dominant in patients with T2DM without albuminuria (OD of 0.24 at CI of 95%).

**Serum Fetuin-A levels and different polymorphisms**

Serum Fetuin-A levels were not different among subjects carrying different alleles of rs248 and rs256 polymorphisms in the three groups. Nevertheless, carriers of the T allele (CT+TT) in polymorphism rs248 and carriers of the G allele (CG+GG) in polymorphism rs256 did show higher mean serum Fetuin-A levels (\( p = 0.018 \) and \( p = 0.014 \), respectively).

**DISCUSSION**

T2DM is a global pandemic that, to date, is considered to be one of the major challenges to our healthcare
Figure 1: Gel electrophoresis of DNA samples after enzyme restriction. (A) Restriction analysis of T256S (c.766C>G) polymorphism in the Fetuin A gene. (405 bp; CC, 212+193 bp; GG, 405+212+193 bp; CG allele bands are shown. Lanes 1,2,3,4,5,6,10 CC alleles; lanes 9: GG alleles; lanes 8: CG alleles; lanes 7, negative control, line M: 100 bp DNA marker. (B) Restriction analysis of T248M (c.742C>T) polymorphism in the Fetuin A gene. (366 bp; CC, 201+165 bp; TT, 366+201+165 bp; CT allele bands are shown. Lanes 2,3,4,5,6,9,10,11,12,: CC alleles; lanes 1: TT alleles; lanes 7,8: CT alleles; Lane M: 100 bp DNA marker).

Figure 2: The distribution of the different alleles (rs248) in the studied groups.

system. Diabetes affects every ethnic group worldwide and its prevalence is increasing— with the greatest rise in low- and middle-income countries, compared to high-income countries. The chronic hyperglycemia observed in DM is associated with pathological changes and long-term damage or dysfunction of various organs, especially the kidneys, eyes, heart, blood vessels and nerves. In this study, we evaluated the relationship of Fetuin-A gene polymorphism and its serum level with early stages of atherosclerosis (measured by CIMT and ABPI), as well as early stages of renal disease, as predicted by estimation of ACR in patients with T2DM. The results of the current study showed that both groups of patients with T2DM had significantly higher mean serum Fetuin-A compared to controls. Moreover, multivariate regression analysis demonstrated significant correlation between insulin resistance and serum Fetuin-A, indicating a role of Fetuin-A in insulin resistance and T2DM. These results are in agreement with multiple previous studies which demonstrated that higher circulating Fetuin-A levels were associated with insulin resistance and increased risk of T2DM. Fetuin-A may play a role in insulin resistance as an inhibitor of the insulin receptor tyrosine kinase activity in the muscle and in the liver, leading to inhibition of insulin signaling. On the other hand, no significant association was demonstrated between serum Fetuin-A levels and DKD, and no significant difference was found between serum Fetuin-A levels in patients with DKD and those without DKD. Also, neither eGFR nor al-
buminuria was found to be associated with serum Fetuin-A levels. In agreement with the results of our study, Jung et al.\textsuperscript{33} reported no association between serum Fetuin-A levels and microvascular complications in patients with T2DM. In contrast, Huddam et al.\textsuperscript{34} reported higher serum Fetuin-A levels in metabolic syndrome patients with microalbuminuria. The current study showed a significant relation between serum Fetuin-A levels and obesity. There was a significant positive correlation between BMI, waist circumference, waist hip ratio, and serum Fetuin-A. Associations between Fetuin-A level and obesity-related parameters have been widely reported in previous studies\textsuperscript{35}. In one study, higher Fetuin-A concentrations were associated with the accumulation of visceral adipose tissue in well-functioning, community-living older persons\textsuperscript{36}. Moreover, a one-year follow-up study showed that gastric bypass surgery among morbidly obese patients resulted in reduction in the concentration of circulating Fetuin-A\textsuperscript{37}.

It is thought that Fetuin-A may be related to the initiation and progression of atherosclerosis\textsuperscript{38}. The results of the current study demonstrated a significant positive correlation between CIMT and serum Fetuin-A, while there was a statistically significant negative correlation between ABPI and serum Fetuin-A. These results are in agreement with those of Yin et al.\textsuperscript{39}, who found that the serum Fetuin-A levels were positively and significantly correlated with CIMT in patients with newly-onset T2DM. Also, Yin et al.\textsuperscript{39} reported that plasma Fetuin-A levels were found to correlate positively and significantly with CIMT. Some previous studies demonstrated a significant association between Fetuin-A and ankle brachial index (ABI). Roos et al.\textsuperscript{40} assessed ABI as a parameter of microvascular disease and demonstrated that type 2 diabetic patients with an ABI < 0.9 had lower Fetuin-A levels than patients with an ABI 0.9-1.3 or > 1.3, and that Fetuin-A was significantly associated with ABI. Lorant et al.\textsuperscript{11} demonstrated that patients with T2DM who additionally suffered from PAD have significantly higher Fetuin-A levels.

With regards to the results of genotyping of Fetuin-A gene polymorphisms, the T allele (rs248) was more dominant in patients with T2DM and without proteinuria (OD of 2.304 at CI of 95%). Regarding rs256, GG polymorphism was more dominant in patients with T2DM without albuminuria (OD of 0.24 at CI of 95%). Very few studies explored these polymorphisms in patients with T2DM. A previous study done on an Egyptian population stated contradictory data regarding rs256 polymorphism since there were no significant differences between the two diabetic groups, with and without proteinuria, or between both of them and control, according to frequencies of the different genotypes and alleles\textsuperscript{42}. Our study showed that serum Fetuin-A levels were not different between subjects carrying different alleles of polymorphism rs248 and rs256 in the three groups. Carriers of the T allele (CT+TT) in polymorphism rs248 and carriers of G allele (CG+GG) in polymorphism rs256 showed higher mean serum Fetuin-A levels. Similarly, Pavlovic et al.\textsuperscript{43} stated that single nucleotide polymorphisms in genes for Fetuin-A,
such as Thr248Met C>T (rs4917) and Thr256 Ser C>G (rs4918), were associated with lower serum Fetuin-A levels and higher mortality rate in RT and CKD patients. Stevinkel et al.\textsuperscript{44} stated that dialysis patients in Sweden showed lower serum Fetuin-A levels in Fetuin-A CG Thr256Ser polymorphism. Axelsson et al.\textsuperscript{45} concluded that Fetuin-A (C→G), Thr256Ser gene polymorphisms affected circulation of serum Fetuin-A levels. In contrast to our study, in an Indonesian population, Thr256Ser subjects with G allele (CG and GG genotypes) had lower serum Fetuin levels compared with patients with CC genotype\textsuperscript{45,46}. Some limitations should be considered in our study. The sample size limited the power to detect the effects of the polymorphisms on microvascular complications of T2DM (rather than early DKD). This cross-sectional study could not exclude patients with non-complicated T2DM who will develop DKD later in the course of the disease. Moreover, patients with T2DM included in the study were receiving insulin or oral hypoglycemic drugs, and we cannot rule out the influence of these drugs on gene expression level.

CONCLUSION

Increased serum Fetuin-A is associated with insulin resistance, increased risk of atherosclerosis, and lower ABPI in patients with T2DM. There is no association between serum Fetuin-A and the development of albuminuria. T allele and GG polymorphisms in rs248 and rs256, respectively, may be associated with lower risk of development of DKD. We recommend that the relationship between polymorphisms in Fetuin-A gene and levels of Fetuin-A should be considered in different populations, and that the role of serum Fetuin-A itself would be further studied in a larger number of patients to further confirm its effect on diabetes and its different complications.

ABBREVIATIONS

| ABPI | Ankle-brachial pressure index |
| ACR | Albumin to creatinine ratio |
| BMI | Body mass index |
| CIMT | Carotid intima-media thickness |
| CKD | Chronic kidney disease |
| DKD | Diabetic kidney disease |
| HOMA2 | Homeostasis Model Assessment 2 |
| PAD | Peripheral artery disease |
| T2DM | Type 2 diabetes mellitus |
| WC | Waist circumference |

ACKNOWLEDGMENTS

This work was supported by Internal Medicine Department (Diabetes Unit), Faculty of Medicine, Alexandria University, Egypt.

AUTHOR’S CONTRIBUTIONS

Study design (Eman Y. Morsy and Azza A. Ismail), Acquisition of data (Hesham A. Elghoneimy and Abd Alhalim G. Smeida), Laboratory tests supervision (Neveen L. Saad), Analysis and interpretation of data (Azza A. Ismail), drafting the article (Neveen L. Saad and Hesham A. Elghoneimy) and critical revision of the manuscript (Eman Y. Morsy and Azza A. Ismail). All authors read and approved the final manuscript.

FUNDING

None.

AVAILABILITY OF DATA AND MATERIALS

Data and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was conducted in accordance with the amended Declaration of Helsinki. The institutional review board approved the study, and all participants provided written informed consent.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care. 2014;37:2934–2939. PMID: 25168125. Available from: https://doi.org/10.2337/dc14-0479.
2. Bandeira SDM, et al. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int J Mol Sci. 2013;14(2):3265–3284. PMID: 23385234. Available from: https://doi.org/10.3390/ijms14023265.
3. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26:77–82. Available from: https://doi.org/10.2337/diaclin.26.2.77.
4. Shah B, Rockman CB, Guo Y, Chesner J, Schwartzbard AZ, Weintraub HS, Adelman MA, Riles TS, Berger JS. Diabetes and vascular disease in different arterial territories. Diabetes Care. 2014;37(6):1636–1642. PMID: 24705616. Available from: https://doi.org/10.2337/dc13-2432.
5. Newman JD, Rockman CB, Kosiborod M, Guo Y, Zhong H, Weintraub HS, et al. Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. American heart journal. 2017;184:114–120. PMID: 28224925. Available from: https://doi.org/10.1016/j.ahj.2016.09.002.
ing Fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2017;41:33–47. PMID: 28643299. Available from: https://doi.org/10.1007/s40618-017-0697-8.

32. Ix JH, Sharma K. Mechanism linking obesity, chronic kidney disease and fatty liver disease: the roles of Fetuin-A, adiponectin and AMPK. J Am Soc Nephrol. 2010;21(3):406–412. PMID:20150538. Available from: https://doi.org/10.1681/ASN.2009080820.

33. Jung CH, Kim BY, Kim CH, Kang SK, Jung SH, Mok JO. Associations of serum Fetuin-A levels with insulin resistance and vascular complications in patients with type 2 diabetes. Diabetes and Vascular Disease Research. 2013;10(5):459–467. PMID: 23811603. Available from: https://doi.org/10.1177/1479164113490766.

34. Huddam B, Azak A, Koçak G, Bayraktar N, Sezer S. The Relationship Between Serum Fetuin-A, Cystatin-C Levels, and Microalbuminuria in Patients With Metabolic Syndrome. Journal of clinical laboratory analysis. 2013;27(4):317–322. PMID: 23852792. Available from: https://doi.org/10.1002/jcla.21605.

35. Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link between obesity and related complications. International journal of obesity. 2015;39(5):734–741. PMID: 25468829. Available from: https://doi.org/10.1038/ijo.2014.203.

36. Ix JH, Wassel CL, Chertow GM, Koster A, Johnson KC, Tylavsky FA, et al. Health Aging and Body Composition Study. Fetuin-A and change in body composition in older persons. The Journal of Clinical Endocrinology & Metabolism. 2009;94(11):4492–4498. PMID: 19820014. Available from: https://doi.org/10.1210/jc.2009-0916.

37. Huang HH, Yeh C, Chen JC, Lee TH, Chen SC, Lee WJ, et al. Does bariatric surgery influence plasma levels of Fetuin-A and leukocyte cell-derived chemotaxin-2 in patients with type 2 diabetes mellitus? PeerJ. 2018;6:e4884. PMID: 29910974. Available from: https://doi.org/10.7717/peerj.4884.

38. Yin L, Cai WJ, Zhu LY, Li J, Su XH, Wang XL, et al. Association between Fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus. Biomed Rep. 2014;2:839–842. PMID: 25279156. Available from: https://doi.org/10.3892/br.2014.356.

39. Yin L, Cai WJ, Zhu LY, Li J, Su XH, Wang XL, et al. Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. International journal of clinical and experimental medicine. 2015;8(1):991.

40. Roos M, Von EM, Heemann U, Rothenbacher D, Brenner H, Breitling LP, Serum FA. cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol. 2010;106:1666–1672. PMID: 20538112. Available from: https://doi.org/10.1016/j.amjcard.2010.01.342.

41. Lorant DR, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schenkaner G, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011;34:156–161. PMID: 20929991. Available from: https://doi.org/10.2337/dc10-0788.

42. El-Batch M, Hamouda HE, Hassan SA, Mohamed WF, El-Horany HE. Preliminary study of biochemical role of serum Fetuin-A level and its gene polymorphism in diabetic patients with microalbuminuria. Journal of Diabetes, Metabolic Disorders & Control. 2015;5:158–164. Available from: https://doi.org/10.15406/jdmdcc.2015.02.00053.

43. Pavlović S, Ogrožević S, Dopsaj V, Novaković I, Bukumrić Z, Naumović R. ASSOCIATION OF FETUIN GENE POLYMORPHISMS WITH CORONARY ARTERY CALCIFICATIONS AND MORTALITY IN RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: MP812. Nephrology Dialysis Transplantation. 2017;32. Available from: https://doi.org/10.1093/ndt/gfx182.MP812.

44. Stervinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, et al. Low Fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney international. 2005;67(6):2383–2392. PMID: 15882283. Available from: https://doi.org/10.1111/j.1523-1755.2005.00345.x.

45. Axelsson J, Wang X, Ketteler M, Qureshi AR, Heimburger O, Bárány P, et al. Is Fetuin-A / α2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease? American journal of nephrology. 2008;28(4):669–676. PMID: 18337634. Available from: https://doi.org/10.1159/000121358.

46. Muzasti RA, Suhardjono S, Purwanto MB, Sembrining RJ. AHSG Thr256Ser Gene Polymorphism as a Predictor of Low Serum Fetuin-A Levels in Indonesian Maintenance Hemodialysis Patients. Open Access Macedonian Journal of Medical Sciences. 2020;8(1):185–190. Available from: https://doi.org/10.3889/oamjms.2020.3520.